Medscape July 30, 2024
PHILADELPHIA — An experimental, cell-based therapy met its primary safety and secondary efficacy endpoints in a phase 2b study on mild Alzheimer’s disease (AD).
The results “exceeded our expectations” in terms of “consistent positive efficacy signals” across different domains, including cognition, quality of life, and neuroimaging results, Joshua Hare, MD, co-founder, chief science officer, and chairman of Longeveron, which developed the treatment, told Medscape Medical News.
The findings were presented on July 28 at the Alzheimer’s Association International Conference (AAIC) 2024.
FDA Fast Track Designation
Earlier this month, the US Food and Drug Administration (FDA) granted Lomecel-B Regenerative Medicine Advanced Therapy designation and Fast Track designation for the treatment of mild AD.
Lomecel-B is a living cell product made from...
Today's Sponsors
Today's Sponsor